Pharmacy chains "inevitable" in Germany, says Celesio chief

27 May 2009

Fritz Oesterle, head of the south German drug wholesale group Celesio, has said that, despite the latest ruling of the European Court of  Justice (Marketletters passim) the establishment of pharmacy chains in  Germany in the medium to longer term is inevitable and unavoidable.

These chains, operated and managed as capital enterprises, would only  be the continuation of a trend that started in the 1980s when  pharmacists started to compete with each other using promotions. This  fashion has now reached its logical next-phase with more and more  flexible competition, he stated.

Earlier, the European Court ruled that the current German legal  position on pharmacy ownership restrictions was in line with European  law with an independent pharmacist only allowed to own and run a  pharmacy. Private capital companies are excluded. The judgement came as  a reverse for Celesio and for pharmacists who want to establish chains  across the country.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight